PPD

Drug developers face pressure to accelerate clinical trials to reduce costs while addressing unmet medical needs. In this Tech Talk video series, PPD’s scientists share how to improve clinical trials while the biopharmaceutical sector continues to face major headwinds. In the final video in the series, John Maier, director CDM, PPD® Laboratory services, and Renay Perry, senior director, project management, review how technology and real-time data integration can improve the clinical trial experience and outcomes.

Pharma and biotech companies strive to accelerate clinical trials to reduce their costs while continuing to meet unmet medical needs. In this Tech Talk video series, PPD’s industry scientists share improvements to clinical trials using innovative data solutions and technological advancements within the central lab.In the 2nd video of the series, Chris Clendening, SVP, lab operations, PPD® Laboratory services, and Tim Rich, VP, PPD Digital and Decentralized solutions, discuss the importance of direct-to-patient and direct-from-patient shipments as it pertains to the intersection of decentralized clinical trials (DCTs).

Drug developers face pressure to accelerate clinical trials to reduce costs while meeting unmet medical needs. In this video series, PPD’s industry scientists share how to improve clinical trials using innovative data solutions within the central lab, real-time data integration, technology and advancements in decentralized clinical trials (DCTs).The first video of the series has Olivia Aspite, executive director, PPD® Laboratory services, and Bryan Neth, manager, business analytics, PPD Laboratory services, discussing how the Phase III COVID-19 vaccine study provided a case study for how to improve clinical trial using innovative solutions.

The first segment of this five-part PPD Tech Talk series on A CMC Roadmap for Cell and Gene Therapies, Katherine Hanson, Ph.D., associate director at PPD Laboratory services, GMP Lab, discusses regulatory considerations for cell and gene therapies.

The second segment of this five-part PPD Tech Talk series Jie Ding, director, and Derek Wood, associate director, at PPD Laboratory services, GMP Lab, discuss pre-requisites such as LC-MS and extractables and leachables (E&L) implications.

In the third part of this five part series, Marc Wolman, labs manager, biopharmaceutical at PPD Laboratory services, GMP Lab, & Jurgen Hannig, senior principal scientist at PPD Laboratory services talk about new analytical tools for cell & gene therapies.

In the fourth part of this five-part series, Ryan Ellefson, director of lab informatics & data analytics, at PPD Laboratory services GMP Lab, and Benjamin Ziehr, senior group leader at PPD Laboratory services GMP Cell Lab, discuss data automation.

In the final segment of this five-part series, A CMC Roadmap to Cell and Gene Therapies, Derrick McVicker, group leader, at PPD Laboratory services, GMP Lab, discusses the transfer of bioanalytical methods to GMP Lab.

This is the first segment of this three-part PPD Tech Talk series on Improving Clinical Trials with Innovative Data Solutions featuring experts Olivia Aspite and Bryan Neth of PPD®, part of Thermo Fisher Scientific.

This is the second segment of this three-part PPD Tech Talk series on Improving Clinical Trials with Innovative Data Solutions featuring experts Chris Clendening and Tim Rich.

This is the final segment of this three-part PPD Tech Talk series on Improving Clinical Trials with Innovative Data Solutions featuring experts John Maier and Renay Perry of PPD®, part of Thermo Fisher Scientific.

A primer for understanding these remarkable therapies and their impacts in clinical trials.

Thursday April 28, 2022 at 11am ET | 10am CT | 8am PT In this new video series, Drug Digest, the Pharmaceutical Technology editors examine the topic of emerging therapies in more detail, covering subjects such as the challenges of scale, the potential benefits of drug delivery innovation, importance of early analytical studies, the evolution of the regulatory landscape, and differences between regional regulatory requirements. Join the editors as they speak with experts from Regulatory Compliance Associates (RCA), the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), and others.

Cell and gene therapies continue to expand rapidly, with an anticipated exponential growth over the next five years. This rapid growth has left an urgent need for industry scientists to gather and share lessons learned concerning bioanalytical, biomarker and regulatory strategies. This series provides insight from PPD Laboratories’ experts into a variety of cell and gene therapy (CGT) modalities in the bioanalytical community, with detailed discussions that leverage their experience with technologies and modalities within this CGT sphere.

*Two Live Airings: Wednesday, June 9, 2021 at 9am EDT| 3pm GMT & Wednesday, June 9, 2021 at 12pm EDT| 9am PDT* Join us for a hybrid/virtual event to celebrate the opening of PPD Laboratories’ newest lab in Suzhou, China. Hear from PPD Laboratories leaders, take a virtual tour, and participate in a live Q&A. *On Demand Until June 9, 2022*